^
No biomarker
Astrocytoma
everolimus
Sensitive
:
A1
No biomarker
Astrocytoma
carmustine
Sensitive
:
A1
No biomarker
Anaplastic Astrocytoma
temozolomide
Sensitive
:
A1
No biomarker
Anaplastic Astrocytoma
PCV
Sensitive
:
A2
BRAF V600E
Astrocytoma
trametinib + dabrafenib
Sensitive
:
A2
No biomarker
Astrocytoma
lomustine + procarbazine hydrochloride + vincristine liposomal
Sensitive
:
A2
BRAF V600E
Astrocytoma
vemurafenib + cobimetinib
Sensitive
:
A2
No biomarker
Astrocytoma
temozolomide gel
Sensitive
:
A2
BRAF V600E
Astrocytoma
cobimetinib
Sensitive
:
A2
BRAF V600E
Astrocytoma
vemurafenib
Sensitive
:
A2
BRAF V600E
Astrocytoma
trametinib
Sensitive
:
A2
BRAF V600E
Astrocytoma
dabrafenib
Sensitive
:
A2
IDH1 R132H
Anaplastic Astrocytoma
temozolomide
Sensitive
:
B
MGMT promoter methylation
Anaplastic Astrocytoma
temozolomide
Sensitive
:
B
BRAF V600
Astrocytoma
vemurafenib
Sensitive
:
C1
BRAF V600
Anaplastic Astrocytoma
vemurafenib
Sensitive
:
C1
IDH1 mutation
Astrocytoma
temozolomide
Sensitive
:
C2
BRAF V600E
Astrocytoma
selumetinib
Sensitive
:
C2
KIAA1549-BRAF fusion
Astrocytoma
selumetinib
Sensitive
:
C2
NRAS mutation
Anaplastic Astrocytoma
atezolizumab + cobimetinib
Sensitive
:
C3
IDH2 mutation
Anaplastic Astrocytoma
PCV
Sensitive
:
C3
IDH1 mutation
Anaplastic Astrocytoma
PCV
Sensitive
:
C3
ABCB1 G412G
Anaplastic Astrocytoma
temozolomide
Sensitive
:
C3
NACC2-NTRK2 fusion
Anaplastic Astrocytoma
larotrectinib
Sensitive
:
C4
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our